Janus Henderson Hrzn Biotec A2 USD |
Performance History | 31/03/2024 |
Growth of 1,000 (EUR) |
Fund | 48.0 | 2.0 | 2.5 | 19.1 | 9.6 | |
+/-Cat | 28.7 | 5.0 | 15.3 | 18.0 | 5.9 | |
+/-Idx | 22.2 | -4.9 | 5.6 | 9.2 | -0.4 | |
Category: Sector Equity Biotechnology | ||||||
Benchmarks: Morningstar Gbl Biotechnolo... |
Key Stats | ||
NAV 25/04/2024 | USD 22.25 | |
Day Change | -3.02% | |
Morningstar Category™ | Sector Equity Biotechnology | |
ISIN | LU1897414303 | |
Fund Size (Mil) 31/03/2024 | USD 261.80 | |
Share Class Size (Mil) 24/04/2024 | USD 56.94 | |
Max Initial Charge | 5.00% | |
Ongoing Charge 14/02/2024 | 1.89% |
Investment Objective: Janus Henderson Hrzn Biotec A2 USD |
The Sub-Fund aims to provide capital growth over the long term. The Fund invests at least 80% of its net assets in equities or equity-related instruments of biotechnology and biotechnology-related companies worldwide. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Daniel Lyons 10/12/2018 | ||
Agustin Mohedas 31/01/2023 | ||
Click here to see others | ||
Inception Date 10/12/2018 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology TR | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Janus Henderson Hrzn Biotec A2 USD | 29/02/2024 |
|
|
Top 5 Holdings | Sector | % |
Vertex Pharmaceuticals Inc | Healthcare | 7.78 |
Amgen Inc | Healthcare | 7.39 |
argenx SE ADR | Healthcare | 3.41 |
Ardelyx Inc | Healthcare | 3.39 |
Sarepta Therapeutics Inc | Healthcare | 3.12 |
Increase Decrease New since last portfolio | ||
Janus Henderson Hrzn Biotec A2 USD |